Last week, the pharmaceutical company, Takeda, was ordered to pay $1.3 million in punitive damages to a former Philadelphia schoolteacher who “argued the drugmaker’s Actos diabetes medicine caused his bladder cancer”, Japan Times writes. Only a few days earlier, that man was awarded over $2.3 million in compensatory damages. According to that Japan Times article,… Continue Reading
Category Archives: Actos & Bladder Cancer
Subscribe to Actos & Bladder Cancer RSS Feed2012 – “Bladder cancer is a real risk with [Actos]”
Posted in Actos & Bladder CancerA recent article published as an editorial in Diabetes Research and Clinical Practice by JA Johnson et al. titled “Balancing the risks and benefits for pioglitazone in type 2 diabetes.” set out to clarify some of the risks and benefits of using the diabetes drug Actos (pioglitazone). The authors state “All therapeutic choices need to… Continue Reading
2012 – Long-term Actos use raises risk for bladder cancer 60-80%
Posted in Actos & Bladder CancerIn 2012, an article was published in Urology titled “Association between pioglitazone and urothelial bladder cancer.” by Y. Barbalat et al. that aimed to “present the current literature reporting the association between pioglitazone and bladder cancer.” To be clear, “pioglitazone” is the chemical name for the diabetes drug, Actos, manufactured by Takeda Pharmaceutical Co. and… Continue Reading
2013 – Actos associated with 56% increased risk for bladder cancer
Posted in Actos & Bladder CancerA recent article published in the August, 2013 edition of Hepatology by CH Chang et al. titled “Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus” studied the connection between certain diabetes drugs and cancer. Thiazolidinediones are a class of diabetes drugs including Actos and others. This team of researchers… Continue Reading
Actos Manufacturers Slated to Pay $9 Billion in Damages
Posted in Actos & Bladder CancerRecently, a federal court has ordered that the manufacturers of the diabetes drug Actos (pioglitazone hydrochloride, by Takeda Pharmaceutical Co. and Eli Lilly & Co.) pay $9 billion in damages when it was determined that these companies failed to warn the public of cancer risks associated with their medication. Though some legal experts believe that… Continue Reading
2011 – Doctor to advocate for Actos paid by manufacturer
Posted in Actos & Bladder CancerIn 2011, Robert Elford Ryder published a report in the medical journal The Lancet titled “Pioglitazone and bladder cancer” which discusses the link between diabetes drug Actos (Tadeka Pharmaceuticals, Inc.) and bladder cancer. At the outset of his piece, Ryder states “In June, 2011, the French and German regulatory bodies suspended pioglitazone over the risk… Continue Reading
2013 – Large study shows Actos raises risk for bladder cancer 30%
Posted in Actos & Bladder CancerIn 2013, a team of researchers led by MT Bazelier published a paper titled “Use of thiazolidinediones and risk of bladder cancer: disease or drugs?”, where it is stated “Pioglitazone, a drug for the treatment of type 2 diabetes mellitus has been associated with bladder cancer in observational studies” but that “Diabetes mellitus itself has… Continue Reading
2014 – Actos users 14% more likely to develop bladder cancer
Posted in Actos & Bladder CancerIn 2014, a team of researchers led by SM Jin published the results of a study that aimed to determined if low doses of pioglitazone (Actos) also raised the risk for bladder cancer among diabetic patients. It has already been demonstrated by many other studies that long-term and high-dose Actos therapy dramatically raises the risk… Continue Reading
2012 – Actos shown to increase risk for bladder cancer
Posted in Actos & Bladder CancerIn 2012, a study was published titled “Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.” that aimed to evaluate the connection between the thiazolidinedione class of diabetes drugs (e.g. Actos) and bladder cancer. The study appeared in Journal of the National Cancer Institute and was prepared by R. Mamtani… Continue Reading
2011 – FDA: Actos raises risk for bladder cancer by 430%
Posted in Actos & Bladder CancerA 2011 article published in Diabetes Care by C. Piccinni et al. titled “Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting.” set out to “analyze the association between pioglitazone [(Actos)] use and bladder cancer through a spontaneous adverse event reporting system for medications.” To obtain data for this study,… Continue Reading
2012 – Long term Actos use doubles risk for bladder cancer
Posted in Actos & Bladder CancerIn 2012, an article by L. Azoulay et al. titled “The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study.” aimed to “determine if the use of pioglitazone is associated with an increased risk of incident bladder cancer in people with type 2 diabetes.” (“Pioglitazone” is… Continue Reading
2011 – Actos dramatically raises risk for bladder cancer
Posted in Actos & Bladder CancerIn 2011, a report by JD Lewis et al. titled “Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.” published in Diabetes Care states “studies and limited human data suggest a possible increased risk of bladder cancer with pioglitazone therapy” and as such, this was a report… Continue Reading
2013 – Two years of Actos use found to double risk for bladder cancer
Posted in Actos & Bladder CancerIn August 2013, an article titled “Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study.” was published by F.Y. Hsiao et al. in the medical journal Drug Safety that aimed to evaluate the connection between rosiglitazone (Avandia) and bladder cancer and between pioglitazone (Actos) and bladder cancer. The… Continue Reading
2013 – Risk for bladder cancer associated with Actos ranges from 21% to 251% increase
Posted in Actos & Bladder CancerIn 2013, a team of researchers led by RM Turner published a report in British Journal of Clinical Pharmacology that evaluated the connection between the thiazolidinedione class of drugs and the onset of bladder cancer. Drugs in that class include diabetes drugs Avandia and Actos. Evaluating 18 previously-conducted studies (13 observational studies and 5 randomized… Continue Reading
2013 – Study shows Actos use raises risk for bladder cancer by 23%
Posted in Actos & Bladder CancerIn 2013, a report by M. Ferwana et al. titled “Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies.” was published in Diabetes Medicine that sought to evaluate the connection between the diabetes drug Actos and new-onset bladder cancer. Living up to its name, this report reviewed data from six previous studies including… Continue Reading
2012 – Huge study links Actos and bladder cancer
Posted in Actos & Bladder CancerIn 2012, a study by Z. Zhu et al. titled “Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis.” aimed to “examine the association between pioglitazone therapy and bladder cancer in patients with diabetes.” To be clear, “pioglitazone” is the chemical name for the diabetes drug Actos, manufactured by Takeda… Continue Reading
2013 – “Increased risk of bladder cancer” associated with Actos
Posted in Actos & Bladder CancerAn article published in a 2013 edition of Tumour Biology titled “Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis.” by S. He et al. aimed to determine the risk for bladder cancer associated with use of pioglitazone (Actos; Tadeka Pharmaceuticals, Inc.). The authors of this paper write… Continue Reading
2012 – Actos associated with 22-75% increased risk for bladder cancer
Posted in Actos & Bladder CancerIn 2012, A. Neumann et al. published a study titled “Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study.” in Diabetologica that studied the risk for bladder cancer among French diabetic patients using Actos (pioglitazone), a drug used to control blood sugar manufactured by Tadeka Pharmaceuticals, Inc. According to… Continue Reading
Washington State Actos Cases
Posted in Actos & Bladder CancerIf anyone in Washington is looking for help with a potential Actos bladder cancer case, give me a call. I have an office in Redmond and am accepting cases from people all across the state, including as far away as Spokane and as close as Bellevue. I am happy to help anyone who is looking… Continue Reading
Actos Lawsuit Discusses History of Actos and Bladder Cancer
Posted in Actos & Bladder Cancer, Drugs, LawsuitsOn September 9th of 2011, an Actos bladder cancer lawsuit was filed by an Actos lawyer in the United States District Court for the Eastern District of Louisiana. The lawsuit was filed on behalf of a Louisiana husband and wife. The husband developed bladder cancer after using Actos for a number of years. The Actos… Continue Reading
I’m Now Able to Help Individuals Who Developed Bladder Cancer While Taking Actos
Posted in Actos & Bladder CancerAbout a year ago I wrote a quick blog post about whether Actos causes bladder cancer. At the time, I wasn’t certain whether there was enough evidence to support filing an Actos bladder cancer lawsuit. I’m now convinced that there is credible medical evidence that shows that Actos causes bladder cancer. I’m therefore accepting cases… Continue Reading
Another Journal Links Actos to Bladder Cancer
Posted in Actos & Bladder Cancer, DrugsEuropean medical authorities have been closely examining the link between Actos and Bladder Cancer for a number of years. An editor for the Irish Medical Times summarized the findings of several studies and concluded that there is an increased risk between the use of Actos and Bladder Cancer: There is a small increased risk… Continue Reading
Diabetes Expert Sees Clear Link Between Actos and Bladder Cancer
Posted in Actos & Bladder Cancer, DrugsDr. V. Mohan, a diabetes expert in India recently weighed in on the link between Actos and bladder cancer: Dr. Mohan says the pioglitazone group was matched against diabetics who were not on the drug. “We learn that there was a slightly increased risk of bladder cancer. Not any other form of cancer, the narrowing… Continue Reading